Affimed Gmbh

Astellas Pharma Gmbh

Biontech Ag

Biontech Se

Ganymed Pharmaceuticals Ag

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

UniversitÄtsmedizin Der Johannes Gutenberg-Universitat Mainz

Ganymed Pharmaceuticals Gmbh

Affimed Therapeutics, Ag

Tron Ggmbh

Tron—translationale Onkologic An Der Universitätsmedzin Der Johannes Gutenberg-Universität Mainz Gemcinnützige Gmbh

Tron - Translationale Onkologie an Der Universitatsmedizen Der Johannes Gutenberg-universitat Mainz Gemeinnutzige Gmbh

Fabrice Le Gall

Ugur Sahin

Uwe Reusch

Sergey Kipriyanov

Melvyn Little

Stefan Knackmuss

Christiane Regina Stadler

Karin Hoffmann

Arne Jendretzki

Ozlem Tureci

Maria Kreuzberg

Markus Fiedler

Tim Beissert

Laura Plum

Julia Holland

Özlem Türeci

Korden Walter

Rita Mitnacht-Kraus

Stefan Jacobs

Kristina Ellwanger

Michael Weichel

Peter Röttgen

Eugene Zhukovsky

Hayat Bähr-Mahmud

Ozlem Türeci

Leyla Fischer

Vera Mick

Melvin Little

Markus Eser

Stefan Weiss

Sergej Kiprijanov

Stefan H J Knackmuss

MSergey Kipriyanov

Stefan Hans Knackmuss

Hayat Bahr-Mahmud

Thorsten Gantke

The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Drug conjugates comprising antibodies against claudin 18.2

The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Agents for treatment of claudin expressing cancer diseases

The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc&#x3b3;RIIIA), and in particular binding molecules that specifically bind the A form Fc&#x3b3;RIII but do not bind to the B form of Fc&#x3b3;RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Anti-CD16 binding molecules

Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.

Human CD3-specific antibody with immunosuppressive properties

Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.

Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types

Growing community of inventors

Mainz, Germany

Fabrice Le Gall